To the full analysis
Amgen stock: growth
AMGNAmgen reported $36.74B in revenue for fiscal 2025, up 9.9% on the prior year, up 7.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.1%
per year from 2006 to 2025, per share 9.5%
Earnings (Annual rate)
5.2%
per year from 2006 to 2025, per share 9.6%
Free cash flow (Annual rate)
3.6%
per year from 2006 to 2025, per share 7.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.6% | 5.4% | 5.1% |
| Revenue per share | 9.5% | 9.1% | 9.5% |
| Earnings | 1.2% | 1.1% | 5.2% |
| Earnings per share | 2.9% | 4.6% | 9.6% |
| Free cash flow | −3.9% | −0.4% | 3.6% |
| Free cash flow per share | −2.3% | 3.1% | 7.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $14.27B | $2.95B | $4.17B |
| 2007 | $14.77B | $3.17B | $4.13B |
| 2008 | $15B | $4.2B | $5.32B |
| 2009 | $14.64B | $4.61B | $5.81B |
| 2010 | $15.05B | $4.63B | $5.21B |
| 2011 | $15.58B | $3.68B | $4.55B |
| 2012 | $17.27B | $4.35B | $5.19B |
| 2013 | $18.68B | $5.08B | $5.6B |
| 2014 | $20.06B | $5.16B | $7.55B |
| 2015 | $21.66B | $6.94B | $8.43B |
| 2016 | $22.99B | $7.72B | $9.52B |
| 2017 | $22.85B | $1.98B | $10.51B |
| 2018 | $23.75B | $8.39B | $10.56B |
| 2019 | $23.36B | $7.84B | $8.53B |
| 2020 | $25.42B | $7.26B | $9.89B |
| 2021 | $25.98B | $5.89B | $8.38B |
| 2022 | $26.32B | $6.55B | $8.79B |
| 2023 | $28.19B | $6.72B | $7.36B |
| 2024 | $33.42B | $4.09B | $10.39B |
| 2025 | $36.74B | $7.71B | $8.1B |
Revenue by segment
How Amgen Inc. makes its money and how that has shifted. Names are as the company reports them.
- Prolia$4.4B12%
- Repatha$3.0B8%
- Otezla$2.3B6%
- Enbrel$2.2B6%
- Evenity$2.1B6%
- Xgeva$2.1B6%
- Other$20.6B56%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Prolia | $4.41B | 12% |
| Repatha | $3.02B | 8.2% |
| Otezla | $2.27B | 6.2% |
| Enbrel | $2.23B | 6.1% |
| Evenity | $2.1B | 5.7% |
| Xgeva | $2.08B | 5.7% |
| Other | $20.64B | 56.2% |
| Total revenue | $36.74B | 100% |
Revenue by region
Where Amgen Inc. generates its revenue.
- United States72%
- Outside the US28%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $18.33B | $18.03B | $18.36B | $17.22B | $18.5B | $18.19B | $18.6B | $19.81B | $23.86B | $26.42B | 71.9% |
| Outside the US | $4.67B | $4.82B | $5.39B | $6.14B | $6.93B | $7.79B | $7.73B | $8.38B | $9.56B | $10.33B | 28.1% |
| Total revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.74B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.